ES2148348T3 - Analogos de glutation y paneles de paralogos que comprenden mimeticos de glutation. - Google Patents

Analogos de glutation y paneles de paralogos que comprenden mimeticos de glutation.

Info

Publication number
ES2148348T3
ES2148348T3 ES94929323T ES94929323T ES2148348T3 ES 2148348 T3 ES2148348 T3 ES 2148348T3 ES 94929323 T ES94929323 T ES 94929323T ES 94929323 T ES94929323 T ES 94929323T ES 2148348 T3 ES2148348 T3 ES 2148348T3
Authority
ES
Spain
Prior art keywords
glutation
alanine
beta
mimetics
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94929323T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Matthew H Lyttle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/126,229 external-priority patent/US5599903A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of ES2148348T3 publication Critical patent/ES2148348T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/9116—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • G01N2333/91165—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1)
    • G01N2333/91171—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1) with definite EC number (2.5.1.-)
    • G01N2333/91177—Glutathione transferases (2.5.1.18)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)

Abstract

UN COMPUESTO DE LA FORMULA (1) Y LOS ESTERES (C1-10) TIPO ALQUILO, (C1-10) TIPO ALQUENILO Y (C7-12) TIPO ARILALQUILO, AMIDAS Y ESTERES/AMIDAS MEZCLADOS DE LOS MISMOS; EN DONDE Z SE SELECCIONA DEL GRUPO QUE CONSISTE EN S, O Y C; N ES 1, 2 O 3; EN DONDE Z ES O O S Y N ES 1, X ES UNA UNIDAD DE HIDROCARBILO (C120) MONO- O DISUSTITUIDA O INSUSTITUIDA QUE OPCIONALMENTE CONTIENE 1 O 2 HETEROATOMOS NO ADYACENTES (O, S O N) Y EN DONDE DICHA SUSTITUCION SE SELECCIONA DEL GRUPO QUE CONSISTE EN HALO, NO, -NO{SUB,2}, -NR{SUB,2}, OR Y SR, EN DONDE CADA R ES, INDEPENDIENTEMENTE, H O ALQUILO INFERIOR (C1-4); EN DONDE CUANDO Z ES S Y N ES 2, UNA X ES COMO SE HA DEFINIDO ARRIBA Y LA OTRA X ES ALQUILO INFERIOR (C1-4); Y EN DONDE CUANDO Z ES C Y N ES 3, UNA X ES COMO SE HA DEFINIDO ARRIBA Y LAS OTRAS DOS X SON, INDEPENDIENTEMENTE, H O ALQUILO INFERIOR (C1-4); Y-CO SE SELECCIONA DEL GRUPO QUE CONSISTE EN {GA} - GLU, {BE} - ASP, GLU, ASP, {GA}GLU - GLY, {BE} - ASP - GLY, GLU - GLY Y ASP - GLY, Y AA{SUB,C} ES UNAMINOACIDO ACOPLADO A TRAVES DE UN ENLACE PEPTIDICO AL RESTO DEL COMPUESTO DE LA FORMULA (1), SON UTILES COMO LIGANDOS DE AFINIDADES, REACTIVOS DE ELUCIONES, INHIBIDORES DE SOLUCIONES, REACTIVOS DE DIAGNOSTICO Y AGENTES TERAPEUTICOS. ESTOS COMPUESTOS Y LOS ANALOGOS DEL GLUTACION DE TRIPEPTIDOS ANALOGOS SE PUEDEN UTILIZAR COMO MIEMBROS DE PANELES PARA OBTENER PERFILES CON UNAS CARACTERISTICAS ESPECIFICAS PARA VARIAS GLUTATION-S-TRANSFERASAS.
ES94929323T 1993-09-24 1994-09-23 Analogos de glutation y paneles de paralogos que comprenden mimeticos de glutation. Expired - Lifetime ES2148348T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/126,229 US5599903A (en) 1992-04-03 1993-09-24 Glutathione analogs and paralog panels comprising glutathione mimics
US08/305,993 US5786336A (en) 1991-04-29 1994-09-19 Target-selective protocols based on mimics

Publications (1)

Publication Number Publication Date
ES2148348T3 true ES2148348T3 (es) 2000-10-16

Family

ID=26824416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94929323T Expired - Lifetime ES2148348T3 (es) 1993-09-24 1994-09-23 Analogos de glutation y paneles de paralogos que comprenden mimeticos de glutation.

Country Status (12)

Country Link
US (1) US5786336A (es)
EP (1) EP0720620B1 (es)
JP (3) JP3503641B2 (es)
AT (1) ATE193302T1 (es)
AU (1) AU693807B2 (es)
CA (1) CA2171453C (es)
DE (1) DE69424678T2 (es)
DK (1) DK0720620T3 (es)
ES (1) ES2148348T3 (es)
GR (1) GR3033230T3 (es)
PT (1) PT720620E (es)
WO (1) WO1995008563A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5679643A (en) * 1987-10-13 1997-10-21 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5908919A (en) * 1993-10-01 1999-06-01 Terrapin Technologies Urethane mediated, GST specific molecular release systems
AU715524B2 (en) * 1995-06-07 2000-02-03 Telik, Inc. Metabolic effects of certain glutathione analogs
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
WO1998009986A1 (en) * 1996-09-02 1998-03-12 The Manchester Metropolitan University S-blocked glutathiones
WO1999037802A1 (en) * 1998-01-21 1999-07-29 Telik, Inc. Methods to identify myelostimulants
JP2002535359A (ja) * 1999-01-27 2002-10-22 テリック，インコーポレイテッド グルタチオン類縁体を含有する治療用組成物
US6783929B1 (en) * 1999-11-02 2004-08-31 Chiron Corporation Biological sample component purification and differential display
US7153682B2 (en) * 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
US7148058B2 (en) * 2000-06-05 2006-12-12 Chiron Corporation Protein microarrays on mirrored surfaces for performing proteomic analyses
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
US7683026B2 (en) * 2003-01-24 2010-03-23 L'oreal Method for synthesizing KPV tripeptide diamide derivatives
PT1833978E (pt) * 2005-01-06 2008-12-02 Telik Inc Tioéteres de tripeptídeo e tetrapeptídeo
US20070154963A1 (en) * 2005-12-30 2007-07-05 Danying Cai Method to determine whether a compound is a cellular GSTpi inhibitor
EP1974739A1 (en) * 2007-03-21 2008-10-01 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Methods and compounds for modulating inflammatory processes
JP5515738B2 (ja) * 2007-07-25 2014-06-11 味の素株式会社 ジベンゾフルベン誘導体の淘汰方法
CN102265160B (zh) * 2008-12-24 2014-07-23 学校法人庆应义塾 肝病标记物、其测定方法、装置和医药品的检验方法
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
CN102939300A (zh) 2010-06-07 2013-02-20 泰立克公司 无溶剂化晶体依泽替米贝盐酸盐d型的制备
JP2013528213A (ja) 2010-06-07 2013-07-08 テリック，インコーポレイテッド エザチオスタットの錠剤製剤
US20120165260A2 (en) * 2010-06-07 2012-06-28 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
BR112013033072B1 (pt) 2011-06-21 2021-04-13 Nitto Denko Corporation Uso de um agente
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
US10093931B2 (en) 2014-06-17 2018-10-09 Nitto Denko Corporation Apoptosis inducer
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
JP2022512077A (ja) 2018-11-16 2022-02-02 日東電工株式会社 Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
JPWO2020230701A1 (es) 2019-05-14 2020-11-19
CN111704566A (zh) * 2020-06-16 2020-09-25 吉尔生化（上海）有限公司 一种N-芴甲氧羰基-γ-（S-三苯甲基-半胱胺基）-L-谷氨酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4830624B1 (es) * 1969-06-19 1973-09-21
JPH07119760B2 (ja) * 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
US4851388A (en) * 1986-01-23 1989-07-25 Pfizer Inc. Heptanoyl-glu-asp-ala-amino acid immunostimulants
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
AU5435990A (en) * 1989-04-13 1990-11-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Monoclonal antibodies to human glutathione s transferase pi
KR970002904B1 (ko) * 1990-04-26 1997-03-12 센쥬 세이야꾸 가부시끼가이샤 S-저급지방산 글루타티온 유도체
EP0481066B1 (en) * 1990-05-07 1995-10-11 Dade International Inc. Method and apparatus for conducting the cytotoxicity assays on tumor cells
IT1248994B (it) * 1990-06-26 1995-02-11 Co Ri T S A S Di Buoso Maria & Processo per la preparazione di s-acil derivati di glutatione composti ottenuti da detto processo e intermedio utile per la loro preparazione
US5204241A (en) * 1990-10-22 1993-04-20 Oxi-Gene Inc. Glutathione-S-transferase mu as a measure of drug resistance
ATE173297T1 (de) * 1991-04-29 1998-11-15 Terrapin Tech Inc Verfahren zur erkennung und behandlung anomaler zellen
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia

Also Published As

Publication number Publication date
EP0720620B1 (en) 2000-05-24
JP2004002442A (ja) 2004-01-08
JPH09506336A (ja) 1997-06-24
CA2171453C (en) 2001-06-12
PT720620E (pt) 2000-11-30
ATE193302T1 (de) 2000-06-15
DK0720620T3 (da) 2000-08-07
AU693807B2 (en) 1998-07-09
CA2171453A1 (en) 1995-03-30
JP4099430B2 (ja) 2008-06-11
JP2004059586A (ja) 2004-02-26
US5786336A (en) 1998-07-28
JP3503641B2 (ja) 2004-03-08
JP4025248B2 (ja) 2007-12-19
WO1995008563A1 (en) 1995-03-30
DE69424678D1 (de) 2000-06-29
EP0720620A1 (en) 1996-07-10
GR3033230T3 (en) 2000-08-31
AU7842194A (en) 1995-04-10
DE69424678T2 (de) 2000-09-07

Similar Documents

Publication Publication Date Title
ES2148348T3 (es) Analogos de glutation y paneles de paralogos que comprenden mimeticos de glutation.
ES2173400T3 (es) Composiciones que contienen cinc para administracion oral que incluyen un compuesto de cobre y un aminoacido.
PL319833A1 (en) Compounds and composition for carrying active media
NZ508721A (en) Increased action of unstable a dipeptidyl peptidase IV inhibitors by conjugating them with a dipeptide in a pharmaceutical formulation for mammalian use
AU8772691A (en) New compounds
AU633142B2 (en) Pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation and the use thereof, and pharmaceuticals based on these compounds
FI862882A0 (fi) 1-substituerade oxindol-3 -karboxiamider som antiinflammatoriska och vaerkstillande medel.
KR960701661A (ko) AIDS치료용 약제학적 배합물중의 HIV프로테아제 억제제(HIV protease inhibitors in pharmaceutical combinations for the treament of AIDS)
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
EA199900580A1 (ru) Фармацевтические производные аминофосфоновой кислоты
YU48670B (sh) POSTUPAK ZA DOBIJANJE (2R,3R)-CIS-Гџ-FENILGLICIDNE KISELINE
NZ336793A (en) Method for stabilizing peptides by adding an organic acid and then lyophilizing the peptide mixture
NO20011946L (no) Mangansammensetninger og fremgangsmåter for MRI
CA2018751A1 (en) Stable freeze dried polyhematoporphyrin ether/ester composition
FI901847A0 (fi) Skyddade aminosyror och foerfarande foer deras framstaellning.
BR9907990A (pt) Sequência de oligonucleotideos complementares aos genes tiorredoxina ou tiorredoxina reductase e métodos de utilização dos mesmos para modular o crescimento de células
DE60103619D1 (de) Pharmazeutische zubereitungen enthaltend alginate
EA199700095A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая индолкарбоновую кислоту
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
JPS6416799A (en) H-pth (1-34) composition and its preparation
ATE103890T1 (de) Neue acylaminosaeurederivate enthaltende arzneimittel und diaetetika.
DE3175733D1 (en) An orally administered drug form comprising a glycosidic antibiotic and an adjuvant
IE831399L (en) Pharmaceutical composition containing meptazinol and¹ibuprofen.
ATE206048T1 (de) Zur topischen applikation bestimmte diclofenac- lösung
FR2622578B1 (fr) Nouveaux derives de l'acide aminopimelique, leur procede de preparation et leur application comme medicaments

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 720620

Country of ref document: ES